4.4 Article

A 2012 Evidence-Based Algorithm for the Pharmacotherapy for Obsessive-Compulsive Disorder

Journal

CURRENT PSYCHIATRY REPORTS
Volume 14, Issue 3, Pages 211-219

Publisher

SPRINGER
DOI: 10.1007/s11920-012-0268-9

Keywords

Obsessive-compulsive disorder; OCD; Pharmacotherapy; Anxiety disorders; Algorithm; Treatment; Evidence-based; Primary care

Categories

Funding

  1. Abbott Laboratories
  2. AstraZeneca
  3. Eli Lilly and Company
  4. GlaxoSmithKline
  5. Jazz Pharmaceuticals
  6. Johnson Johnson
  7. H. Lundbeck A/S
  8. Orion Pharma
  9. Pfizer
  10. Pharmacia
  11. Roche
  12. Servier
  13. Solvay Pharmaceuticals
  14. Sumitomo
  15. Takeda
  16. Tikvah
  17. Wyeth
  18. Wellcome
  19. Cephalon
  20. ECNP
  21. Martin Dunitz Press
  22. Oxford University Press
  23. Janssen Pharmaceutica
  24. Bristol-Myers Squibb
  25. International College of OC Spectrum Disorders
  26. National Council for Scientific and Technological Development (CNPq)
  27. Rio de Janeiro State Research Support Foundation (FAPERJ)
  28. National Institute of Mental Health
  29. Neuropharm Ltd
  30. Transcept Pharmaceuticals
  31. Up to Date
  32. Cambridge University Press
  33. Grants-in-Aid for Scientific Research [22591294] Funding Source: KAKEN

Ask authors/readers for more resources

There is a need to synthesize the growing body of literature on the pharmacotherapeutic management of patients with obsessive-compulsive disorder for clinicians working at a primary care level. We have aimed to generate a simple, easy-to-follow algorithm for the primary care practitioner. This seven-step algorithm addresses diagnosis of obsessive-compulsive disorder, initiation of pharmacotherapy, monitoring and maintenance treatment, and guidelines for the management of patients who are resistant to initial therapy. In creating this algorithm, we have drawn on the body of published evidence, as well as on expert opinion.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available